Strong Q3 results for Baxter despite Colleague pump woes
This article was originally published in Clinica
Executive Summary
With its third-quarter earnings jumping 12% from the previous year to reach $0.47 per share, Baxter has surprised analysts by holding up well even under the cloud of its Colleague infusion pump recall.